Glucose Viaflo Baxter

Glucose Viaflo Baxter is an intravenous glucose solution marketed in the European Union. It contains the simple sugar glucose as its sole active ingredient and is supplied in a sterile liquid form for infusion. The product is intended for use by healthcare professionals in clinical settings to provide a source of carbohydrate and maintain fluid balance when administered intravenously. Administration follows standard aseptic techniques and institutional protocols.

Glucose Viaflo Baxter is used in medical practice to address specific metabolic and fluid needs during patient care.

- Provide an immediate source of glucose for patients unable to intake nutrition orally. - Support energy metabolism in perioperative and critical‑care settings. - Assist in the correction of hypoglycemia when rapid carbohydrate replacement is required. - Contribute to fluid replacement and electrolyte balance as part of a balanced intravenous therapy regimen. - Serve as a carrier for compatible intravenous medications that require a glucose-containing diluent. - Facilitate the maintenance of blood osmolarity during infusion therapy.

When administered intravenously, Glucose Viaflo Baxter may be associated with a range of observed effects, most of which are mild, self‑limiting, and transient.

Common: - Mild hyperglycemia that resolves with monitoring. - Transient increase in serum osmolality. - Local irritation at the infusion site. - Temporary nausea or light‑headedness. - Mild electrolyte shifts, such as a slight decrease in serum potassium. - Transient increase in blood lactate levels, occasionally observed.

Serious: - Severe hyperglycemia requiring medical intervention. - Fluid overload leading to pulmonary edema. - Allergic reaction such as rash, itching, or anaphylaxis. - Severe electrolyte imbalance, including marked potassium shifts that may affect cardiac rhythm. - Rapid infusion causing hypotension or cardiac stress.

Healthcare professionals should observe specific precautions when preparing and administering Glucose Viaflo Baxter to ensure patient safety and product integrity.

- Verify patient identity and confirm indication before infusion. - Use aseptic technique and inspect the solution for particulate matter or discoloration. - Adjust infusion rate according to individual fluid and glucose requirements. - Monitor blood glucose levels regularly during and after administration. - Assess for signs of fluid overload, especially in patients with cardiac or renal impairment. - Ensure compatibility with other intravenous medications; avoid mixing with solutions that may precipitate. - Document the product lot number and expiration date in the patient record.

Glucose Viaflo Baxter may interact with other agents administered intravenously; awareness of potential interactions helps guide safe co‑administration.

Avoid: - Co‑infusion with high‑concentration potassium solutions, which can cause rapid shifts in serum potassium. - Simultaneous administration with hypertonic saline or other high‑osmolarity fluids that may exacerbate fluid overload. - Mixing with calcium-containing solutions may cause precipitation.

Use with caution: - Concurrent use of insulin therapy; glucose infusion may require insulin dose adjustments. - Administration alongside diuretics, especially loop diuretics, as fluid balance may be affected. - Use with caution in patients receiving catecholamines, as glucose can influence hemodynamic responses.